000 | 01922ngm a2200361 a 4500 | ||
---|---|---|---|
001 | HST1529 | ||
003 | UkLoHST | ||
006 | m c | ||
007 | cr|cna|||a|||| | ||
007 | vz|czazum | ||
008 | 080121s2007 enk|||||||||||s|||v|eng d | ||
028 | 5 | 0 |
_a1529 _bHenry Stewart Talks |
035 | _a(UkLoHST)215 | ||
035 | _a(UkLU-K)AC000391620 | ||
040 |
_aUkLU-K _beng _cUkLU-K |
||
100 | 1 |
_aTellier, Zera. _4spk |
|
245 | 1 | 0 |
_aIntravenous immunoglobulins _h[electronic resource] : _bmyth and reality / _cZera Tellier. |
260 |
_aLondon : _bHenry Stewart Talks, _c2007. |
||
300 |
_a1 online resource (1 streaming video file (25 min.) : _bcolor, sound). |
||
490 | 1 |
_aAutoimmunity : etiology, pathogenesis, clinical manifestation and diagnostic methodologies, _x2056-452X |
|
500 | _aAnimated audio-visual presentation with synchronized narration. | ||
500 | _aTitle from title frames. | ||
505 | 0 | _aContents: The use of intravenous immunoglobulins (IVIg) as therapeutic proteins -- Use of IVIg to provide effective treatment for autoimmune thrombocytopenic purpura -- Use of IVIg in a large range of autoimmune or systemic inflammatory diseases -- Increase in worldwide IVIg demand -- Increased evidence showing the efficacy of IVIg -- Mechanisms for the action of IVIg in autoimmune diseases -- Need for classification of the recommendations for use -- Clinical indications for IVIg therapy. | |
506 | _aAccess restricted to subscribers. | ||
538 | _aMode of access: World Wide Web. | ||
650 | 2 | _aAutoimmune Diseases. | |
650 | 2 | _aAutoimmunity. | |
650 | 2 |
_aImmunoglobulins, Intravenous _xtherapeutic use. |
|
650 | 2 | _aResearch. | |
830 | 0 |
_aHenry Stewart talks. _pBiomedical & life sciences collection. _pAutoimmunity : etiology, pathogenesis, clinical manifestation and diagnostic methodologies. |
|
856 | 4 | 0 | _uhttps://hstalks.com/bs/215/ |
856 | 4 | 2 |
_uhttps://hstalks.com/bs/p/23/ _3Series |
999 |
_c78136 _d78136 |